Kristian Helin
Epigenetics researcher who leads the ICR, the academic institution with the most cancer drug discoveries.
Kristian Helin became Chief Executive of the ICR in 2021 after leading the cell biology programme at Memorial Sloan Kettering and the Biotech Research and Innovation Centre in Copenhagen. His research concerns polycomb complexes, histone demethylases, and epigenetic drug targets.
| Title | Journal | Year |
|---|---|---|
| The polycomb group protein EZH2 is required for mammalian circadian clock function | PLoS Biology | 2014 |
Pages like this
not linked directly; found by shared links- IdeaBlock the chemical switch that lets cells hide from treatment
Shares EZH2, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET).
- ProductTazemetostat
Shares EZH2, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET).
- ProductMevrometostat
Shares EZH2, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET).
- IdeaUnmask hidden antigens with a short epigenetic course before immunotherapy
Shares EZH2, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET).
- IdeaGroup trials by broken mechanism, not by organ or single mutation
Shares EZH2, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET).
- PathwayDrug-tolerant persister cells
Shares EZH2, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET).
- PathwayTranscriptional machinery & addiction
Shares EZH2, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET).
- PathwayEpigenetic reprogramming
Shares EZH2, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET).